About Prof. Zhang Li
Prof. Zhang Li (张力) is one of China's most distinguished medical oncologists, serving as Chief Physician, Professor, Doctoral Supervisor, and Deputy Director of the Lung Cancer Research Institute at Sun Yat-sen University Cancer Center (SYSUCC) in Guangzhou. As Chairman of the Chinese Society of Clinical Oncology (CSCO) Immunotherapy Committee and a chief Multidisciplinary Team (MDT) expert, Prof. Zhang stands at the forefront of thoracic oncology, targeted cancer therapy, and cancer immunotherapy both nationally and globally.
With more than three decades of clinical practice and translational oncology research, Prof. Zhang has pioneered groundbreaking strategies for patients with advanced, refractory, and recurrent malignancies. He is widely celebrated for his clinical precision in tailoring targeted therapy regimens, overcoming complex drug resistance mechanisms, and designing innovative clinical trials that have established new standards of cancer care.
Core Clinical Specializations & Oncological Innovations
1. Advanced Non-Small Cell Lung Cancer (NSCLC)
Prof. Zhang is an internationally recognized authority on the personalized systemic management of advanced and metastatic NSCLC. He specializes in precision molecular profiling—incorporating next-generation sequencing (NGS) and liquid biopsy technologies—to identify actionable driver mutations including EGFR, ALK, ROS1, RET, MET, KRAS, and HER2, ensuring every patient receives optimal first-line and subsequent targeted regimens.
2. Overcoming EGFR-TKI Drug Resistance
A critical focus of Prof. Zhang's clinical and academic endeavors is addressing resistance to EGFR tyrosine kinase inhibitors (EGFR-TKIs). Having extensively researched resistance pathways arising after first-, second-, and third-generation inhibitors (such as osimertinib), Prof. Zhang provides advanced salvage options. His clinical practice leverages novel combination protocols, next-generation targeted agents, antibody-drug conjugates (ADCs), and individualized multi-agent regimens to successfully regain disease control for heavily pretreated patients.
3. Nasopharyngeal Carcinoma (NPC) & Head and Neck Tumors
Hailing from Sun Yat-sen University Cancer Center—the world's foremost clinical and research center for nasopharyngeal carcinoma—Prof. Zhang is an internationally renowned leader in medical therapy for recurrent or metastatic NPC. He has pioneered chemotherapy-free and immunotherapy-combination regimens, achieving remarkable tumor response rates, prolonging survival, and significantly improving quality of life for patients facing advanced disease.
4. Immuno-Oncology & Novel Therapeutic Modalities
As the Chairman of the CSCO Immunotherapy Committee, Prof. Zhang is an influential architect of cancer immunotherapy in China. His practice encompasses immune checkpoint inhibitors (PD-1/PD-L1, CTLA-4), bispecific and multi-specific antibodies, cellular immunotherapies, and innovative immunomodulatory combinations designed to overcome primary and acquired immune evasion in solid tumors.
5. Multidisciplinary Team (MDT) Leadership
Prof. Zhang serves as a core decision-maker across complex cancer MDTs at SYSUCC. He routinely leads multidisciplinary evaluations for difficult cases involving oligometastatic progression, central nervous system (CNS) brain and leptomeningeal metastases, and rare histologic variants, synthesizing surgical, radiotherapeutic, and systemic oncology strategies into cohesive care plans.
Academic Leadership, Clinical Trials & Landmark Publications
Prof. Zhang Li is recognized as one of the most prolific and impactful clinical investigators in Asia. His translational research and investigator-initiated trials have repeatedly shaped clinical oncology practice worldwide:
- High-Impact Publications: As corresponding author and lead investigator, Prof. Zhang has published numerous landmark clinical studies in top-tier international journals, including The Lancet Oncology, Journal of Clinical Oncology (JCO), JAMA Oncology, and Nature Medicine.
- Guideline Author & Expert Consensus: He has led and participated in authoring key clinical practice guidelines for CSCO and national cancer treatment consensus panels, directly shaping how non-small cell lung cancer and nasopharyngeal carcinoma are managed across medical centers.
- Leading Phase I–III Global Clinical Trials (2024–2025): Prof. Zhang serves as Principal Investigator (PI) for multiple international multicenter Phase I, II, and III clinical trials. These ongoing trials evaluate cutting-edge bispecific antibodies, fourth-generation EGFR inhibitors, next-generation ADCs, and novel targeted molecules, granting eligible patients early access to next-wave oncology breakthroughs.
Sun Yat-sen University Cancer Center (SYSUCC) Profile
Located in Guangzhou, Sun Yat-sen University Cancer Center is officially designated as a National Cancer Center in China and consistently ranks among the top three specialized oncology institutions nationwide. Renowned for its enormous clinical volume, state-of-the-art diagnostic laboratories, and world-class clinical research infrastructure, SYSUCC serves as a beacon of advanced cancer medicine in the Guangdong-Hong Kong-Macao Greater Bay Area and attracts patients from across Asia and around the globe.
Why International Patients Choose Prof. Zhang Li
- Unmatched Expertise in Complex Resistance: When standard treatments or third-generation targeted drugs fail, Prof. Zhang offers deep insight into molecular resistance mechanisms and access to tailored salvage protocols.
- Direct Gateway to Leading-Edge Clinical Trials: Patients with limited standard therapeutic alternatives can be evaluated for cutting-edge clinical trials running under Prof. Zhang's supervision.
- High Clinical Volume & Rapid Diagnostic Turnaround: Backed by SYSUCC's advanced molecular pathology, NGS sequencing, and imaging facilities, diagnosis and therapy adjustment happen with exceptional speed and rigor.
- Cost-Effective, World-Class Oncology Care: International patients benefit from access to globally approved innovative therapeutics and clinical care at a fraction of the cost found in Western medical centers.
The Patient Journey: Navigating Care with CMCS
As an independent medical concierge organization, China Medical Concierge – Shanghai (CMCS) coordinates access for international patients seeking expert consultation and specialized oncology care with leading medical authorities such as Prof. Zhang Li:
- Step 1: Comprehensive Record & Pathology Evaluation: We collect and organize your medical history, recent contrast-enhanced imaging (CT, MRI, PET-CT), and molecular profiling/NGS reports for preliminary evaluation by specialist teams.
- Step 2: Strategy Review & Clinical Trial Screening: If you are seeking second opinions or exploring novel therapeutic options, we assist in determining eligibility criteria for relevant clinical trials or specialized MDT consultations.
- Step 3: Travel, Visa & Logistics Coordination: CMCS assists with medical visa invitation documentation, local travel planning in Guangzhou, airport greeting, and tailored accommodation arrangements.
- Step 4: On-Site Medical Concierge & Clinical Translation: Throughout your outpatient visits, diagnostic appointments, and inpatient stays at SYSUCC, dedicated bilingual medical liaisons provide real-time translation and administrative coordination.
- Step 5: Follow-Up & Long-Term Monitoring: After returning home, CMCS facilitates follow-up communication, ongoing test monitoring, and remote physician follow-up coordination.
Frequently Asked Questions
Can patients with resistance to 3rd-generation EGFR-TKIs still receive effective treatment?
Yes. Resistance mechanisms to third-generation TKIs (such as osimertinib) can be identified through tissue or liquid biopsy next-generation sequencing (NGS). Identified pathways—such as MET amplification, secondary EGFR mutations (e.g., C797S), HER2 alteration, or histological transformation—often qualify patients for combination regimens, targeted ADCs, or clinical trials investigating fourth-generation agents.
How can international patients access novel clinical trials led by Prof. Zhang Li?
Enrollment in clinical trials requires strict adherence to protocol inclusion and exclusion criteria, including measurable disease, specific biomarker expressions, and adequate organ function. CMCS assists patients by organizing their comprehensive medical dossiers in English for initial protocol pre-screening before arrival.
What records are needed before booking a consultation?
You should prepare recent medical summaries, full-dose pathology reports, immunohistochemistry (IHC) slides or reports, molecular genetic testing (NGS) results, and digital DICOM files of recent CT, MRI, or PET scans performed within the past 4–8 weeks.
How long should international patients plan to stay in Guangzhou?
An initial comprehensive outpatient evaluation and diagnostic workup typically requires 3 to 7 business days. If initiation of inpatient or specialized day-ward therapy is recommended, patients generally stay for 1 to 2 weeks for cycle initiation and toxicity monitoring.
Schedule Your Consultation with Prof. Zhang Li
If you or a loved one is navigating advanced lung cancer, nasopharyngeal carcinoma, or targeted therapy resistance, our medical concierge team is here to assist with expert coordination and appointment scheduling.
Contact CMCS Medical Concierge:
- Email: contract@medicalsh.com
- WhatsApp: https://wa.me/message/3AM6KAGCW2BAD1
- Website: www.medicalsh.com
0 comments